LB Pharmaceuticals names Susan Kozauer as chief medical officer

LB Pharmaceuticals Inc (Nasdaq: LBRX) announced on September 15, 2026 that Susan G. Kozauer, M.D. had been appointed Chief Medical Officer, effective September 14, 2026.¹

Kozauer, age 54, most recently served as Senior Vice President, Head of Clinical Development at Centessa Pharmaceuticals from August 2025 to September 2026¹, a unit the release describes as a wholly owned subsidiary of Eli Lilly and Company, where she led clinical development and strategy for its orexin agonist portfolio¹. Before that, she was Vice President in Clinical Development at Intra-Cellular Therapies, Inc. from November 2017 to August 2025.¹ At Intra-Cellular, she oversaw clinical development of multiple compounds, including U.S. and global late-stage development of CAPLYTA (lumateperone) in adult and pediatric indications.¹

Under her employment agreement, Kozauer is entitled to an initial annual base salary of $515,000 and an annual discretionary bonus with a target of 40% of that salary.¹ She will also receive a one-time cash sign-on bonus of $150,000, paid within 30 days of her start date, with 50% earned on each of the first and second anniversaries, subject to repayment if her employment ends before the second anniversary.¹ The company will grant her an option to purchase 200,000 shares of common stock, vesting over four years with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.¹

If terminated without cause outside a change-of-control window, she is entitled to continued base salary for nine months and COBRA reimbursement for up to nine months.¹ In a change-of-control scenario, terms include a lump sum of one year's base salary plus 150% of her target bonus, COBRA reimbursement for up to 12 months, and acceleration of unvested equity awards.¹

The company said its lead candidate LB-102 is heading toward topline results from the Phase 3 NOVA-2 trial in schizophrenia in the first half of 2027.¹